Therefore, the assay described, in which of the phosphorylation of ATM-specific targets (SMC1 and KAP1) are collectively assessed, could provide a reliable way to determine ATM function in cancer patients and guide subsequent treatment options. The gene discussed is SMC1A; the disease is cancer.